Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate- controlled positive pressure infusion

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 778-788

  Brust, David ^a   Feden, Jeffrey ^a   Farnsworth, Julie ^a   Amir, Cyrus ^a   Broaddus, William C ^a   Valerie, Kristoffer ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer gene therapy; Drug delivery; Halogenated pyrimidines; Osmotic pump; Radiation

Indexed keywords

BROXURIDINE; DNA; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; FEMALE; GENE EXPRESSION; GENE THERAPY; GLIOMA; HERPES SIMPLEX VIRUS; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RADIOSENSITIVITY; RAT; TUMOR GROWTH; TUMOR REGRESSION;

ADENOVIRIDAE; ALEUTIAN MINK DISEASE PARVOVIRUS (STRAIN G); ANIMALIA; DNA VIRUSES; HERPES; SIMPLEXVIRUS;

EID: 0034077052     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700168     Document Type: Article

References (37)

1. Djordjevic B, Szybalski W. Incorporation of 5-bromo and 5-iododeoxyuridine into deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med. 1960;112:509-531.
2. Mitchell JB, Russo A, Cook JA, Straus KL, Glatstein E. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int J Radiat Biol. 1989;56:827-836.
3. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ Jr. Enhancement of X ray-induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys. 1987;13:733-739.
4. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys. 1984;10:1399-1406.
5. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys. 1990;18:1393-1398.
6. Goffman TE, Dachowski LJ, Bobo H, et al. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol. 1992;10: 264-268.
7. Perez-Cruet MJ, Trask TW, Chen SH, et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res. 1994;39:506-511.
8. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
9. Eck SL, Alavi JB, Alavi A, et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther. 1996;7: 1465-1482.
10. Broaddus WC, Chen ZJ, Prabhu SS, et al. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery. 1997;41:908-915.
11. Valerie K, Singhal A. Host-cell reactivation of reporter genes introduced into cells by adenovirus as a convenient way to measure cellular DNA repair. Mutat Res. 1995;336: 91-100.
12. Sidak A. Rectangular confidence for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62:626-633.
13. Cooper GM. Phosphorylation of 5-bromodeoxycytidine in cells infected with herpes simplex virus. Proc Natl Acad Sci USA. 1973;70:3788-3792.
14. Greer S, Schildkraut I, Zimmerman T, Kaufman H. 5-Halogenated analogs of deoxycytidine as selective inhibitors of the replication of herpes simplex viruses in cell culture and related studies of intracranial herpes simplex virus infections in mice. Ann N Y Acad Sci. 1975;255:359-365.
15. Gratzner HG. Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science. 1982;218:474-475.
16. Iliakis G, Wright E, Ngo FQ. Repair and fixation of potentially lethal damage (PLD) as demonstrated by delayed plating or incubation with araA in contact-inhibited refed plateau-phase C3H mouse embryo 10 T1/2 cells grown in the presence of BrdUrd. Radiat Environ Biophys. 1987;26:47-62.
17. Iliakis G, Kurtzman S, Pantelias G, Okayasu R. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat Res. 1989;119:286-304.
18. Kriss J, Revesz L. The distribution and rate of bromodeoxyuridine and bromodeoxycytidine incorporation in the mouse and rat. Cancer Res. 1962;22:254-265.
19. Cooper G, Greer S. The effect of inhibition of cytidine deaminase by tetrahydrouridine on the utilization of deoxycytidine and 5-bromodeoxycytidine for deoxyribonucleic acid synthesis. Mol Pharmacol. 1973;9:698-703.
20. Kreis W, Chan K, Budman DR, et al. Effect of tetrahydrouridine on the clinical pharmacology of 1-β-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 1988;48:1337-1342.
21. Kreis W, Budman DR, Chan K, et al. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase): a pilot study. Leukemia. 1991;5:991-998.
22. Grant S, Bhalla K, McCrady C. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2′-deoxycytidine and 1-β-D-arabinofuranosylcytosine in human leukemia cells. Leuk Res. 1991;15:205-213.
23. Broaddus WC, Prabhu SS, Gillies GT, et al. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg. 1998;88:734-742.
24. Cook JA, Glass J, Lebovics R, et al. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine. Cancer Res. 1992;52:719-725.
25. Epstein AH, Lebovics RS, Goffman T, et al. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J Natl Cancer Inst. 1994;86:1775-1780.
26. Erikson R, Szybalski W. Molecular radiobiology of human cell lines: comparative radiosensitizing properties of 5-halodeoxycytidines and 5-halodeoxyuridines. Radiat Res. 1963;20:253-262.
27. Perez LM, Mekras JA, Briggle TV, Greer S. Marked radiosensitization of cells in culture to X ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine and inhibitors of pyrimidine biosynthesis. Int J Radiat Oncol Biol Phys. 1984;10:1453-1458.
28. Lawrence TS, Davis MA. Selective radiosensitization and cytotoxicity of human melanoma cells using halogenated deoxycytidines and tetrahydrouridine. Int J Radiat Oncol Biol Phys. 1989;16:1243-1246.
29. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res. 1994;54:6053-6056.
30. Kim JH, Kim SH, Kolozsvary A, Brown SL, Kim OB, Freytag SO. Selective enhancement of radiation response of herpes simplex virus thymidine kinase-transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys. 1995;33:861-868.
31. Kim SH, Kim JH, Kolozsvary A, Brown SL, Freytag SO. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. J Neurooncol. 1997; 33:189-194.
32. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
33. Meyn RE. Apoptosis and response to radiation: implications for radiation therapy. Oncology. 1997;11:349-356.
34. Phillips TL, Bodell WJ, Uhl V, Ross GY, Rasmussen J, Mitchell JB. Correlation of exposure time, concentration, and incorporation of IdUrd in V-79 cells with radiation response. Int J Radiat Oncol Biol Phys. 1989; 16:1251-1255.
35. Colombo BM, Benedetti S, Ottolenghi S, et al. The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther. 1995;6:763-772.
36. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56:2697-2702.
37. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54:6228-6234.